Qingdao Baheal Medical Inc. Qingdao Baheal Medical Inc. (301015.SZ) engages in the research, development, production, wholesale, retail, and commercialization of pharmaceutical products in China. Founded in 2005 and headquartered in Qingdao, China, the company, a subsidiary of BAHEAL Pharmaceutical Holdings Limited, specializes in modern traditional Chinese medicine and high-end controlled-release formulations; it offers a diverse product matrix including bone health drugs such as vitamin D calcium chewable tablets, digestive drugs, liver disease drugs, urological drugs, diabetes drugs, over-the-counter (OTC) and general health products, OTX and prescription medicines, oncology drugs, and high-end medical devices. Baheal Medical operates through segments encompassing brand operations, pharmaceutical wholesale and distribution, and retail, with R&D and production bases in Qingdao and Shanghai, serving clinical practices nationwide via an extensive sales and marketing network. Recent developments include the 2024 acquisition of a 60.199% stake in Shanghai Baheal Pharma Co., Ltd. for CNY 880 million to integrate resources and extend its industrial chain into pioneering innovations; establishment of Baheal Medical (Guangdong) Co., Ltd. with CNY 50 million capital for medical device leasing and sales; strategic investment in CANbridge Pharmaceuticals Inc. for approximately HK$100 million alongside an exclusive commercial services agreement for rare disease products in mainland China, Hong Kong, and Macau; a partnership with Tianjin Jikun Pharmaceutical Technology Co., Ltd. granting rights to acquire the idiopathic pulmonary fibrosis drug JK1033 and a 24% equity stake; and a commercialization collaboration with Shanghai Roche Pharmaceuticals Ltd. to promote MabThera.